CollPlant Biotechnologies (FRA:CPT) 3-Month Share Buyback Ratio: -12.65% (As of Mar. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CPT CollPlant Biotechnologies Ltd FRA:CPT
29 GF Score
Price €0.27
GF Value €0.25
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is CollPlant Biotechnologies 3-Month Share Buyback Ratio?

CollPlant Biotechnologies FRA:CPT 29 3-Month Share Buyback Ratio is -12.65 as of Mar. 2026. GuruFocus rates FRA:CPT with a GF Score™ of 29/100 and a GF Value™ of €0.25 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. CollPlant Biotechnologies's current 3-Month Share Buyback Ratio was -12.65%.


CollPlant Biotechnologies  (FRA:CPT) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


CollPlant Biotechnologies 3-Month Share Buyback Ratio Related Terms


FRA:CPT vs XBIO, JUNS, ADIL: 3-Month Share Buyback Ratio Comparison

For the Biotechnology subindustry, CollPlant Biotechnologies's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CollPlant Biotechnologies 3-Month Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's 3-Month Share Buyback Ratio falls into.


FRA:CPT
29GF Score
CollPlant Biotechnologies Ltd FRA:CPT
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CollPlant Biotechnologies 3-Month Share Buyback Ratio Calculation

CollPlant Biotechnologies's 3-Month Share Buyback Ratio for the quarter that ended in Mar. 2026 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Dec. 2025 ) - Shares Outstanding (EOP) (Mar. 2026 )) / Shares Outstanding (EOP) (Dec. 2025 )
=(12.803 - 14.423) / 12.803
=-12.65%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 3-Month Share Buyback Ratio of -12.65 mean?
CollPlant Biotechnologies (FRA:CPT) has a 3-Month Share Buyback Ratio of -12.65 as of Mar. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for CollPlant Biotechnologies and its competitors.
Is CollPlant Biotechnologies' 3-Month Share Buyback Ratio too high?
CollPlant Biotechnologies' current 3-Month Share Buyback Ratio is -12.65. Overall, CollPlant Biotechnologies has a GF Score™ of 29/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' 3-Month Share Buyback Ratio compare to XBIO and JUNS?
CollPlant Biotechnologies' 3-Month Share Buyback Ratio of -12.65 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for CollPlant Biotechnologies and its competitors. CollPlant Biotechnologies's current 3-Month Share Buyback Ratio is -12.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (FRA:CPT) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.25, compared to a current price of €0.27 — trading 6.4% above its estimated fair value. The current 3-Month Share Buyback Ratio is -12.65. CollPlant Biotechnologies' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For CollPlant Biotechnologies (FRA:CPT), the current 3-Month Share Buyback Ratio is -12.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CollPlant Biotechnologies (FRA:CPT) Overvalued in 2026?

Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued. The current stock price of €0.27 is trading 6.4% above its estimated GF Value™ of €0.25. GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.

Key valuation signals for FRA:CPT:

  • 3-Month Share Buyback Ratio: -12.65
  • GF Value™: €0.25 vs. price of €0.27 (6.4% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the FRA:CPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CollPlant Biotechnologies Business Description

Other Exchanges CLGN:USA
Address 4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
29GF Score

Get the complete analysis for FRA:CPT

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.27
Price
€0.25
GF Value